Renal protective effects of erythropoietin on ischemic reperfusion injury.
While the problem of organ shortage has not yet been solved, the number of patients who need to be treated with dialysis due to end-stage renal disease (ESRD) is increasing each year. With the aim of eliminating dialytic therapy as much as possible, the opportunities for organ donation from expansive criteria donor (ECD) or marginal donors due to cardiac death have been increasing. With the purpose of extracting organs in a state in which the function is preserved as much as possible, we reexamined the conditions of tissue disorders resulting from temporary ischemia of the organs as well as changes in tissue function and the effects on the preservation of renal function over time by using rat models in order to clinically utilize erythropoietin, which has inhibitory effects on ischemia-reperfusion disorder, as has been conventionally reported. With 8- to 9-week-old Wister male rats, after the right kidney had been resected under general anesthesia, the left renal artery was clamped to inhibit the blood flow for 45 min. At 30 min before inhibiting the blood flow and after releasing the inhibited blood flow, 100 U/kg of recombinant human erythropoietin (rhEPO) was administered via the inferior vena cava and the abdominal cavity, and then the tissues and blood samples were extracted at 6 and 24 h after the release. The renal tissue specimens were evaluated using H&E staining and TUNEL staining in order to observe differences in the expression of apoptosis as well as the renal function and changes in the emergence of active oxygen were investigated by using samples that had been obtained from drawn blood. Moreover, we examined the degree of renal dysfunction by means of neutrophil gelatinase-associated lipocalin (NGAL) in the spot urine samples. The changes in renal function, which were observed according to the serum creatinine level, showed that the renal function was preserved with a significant difference in the rhEPO administration group. The liver deviation enzymes, which had also shown increases in the serum as well as the occurrence of renal dysfunction, showed clear decreases in the serum, even though changes with a significant difference were not observed in the rhEPO administration group. The active oxygen did not show changes before and after ischemia-reperfusion nor changes due to the rhEPO administration. When examining the status of apoptosis in the tissues, apoptosis was shown to be inhibited due to the rhEPO administration. It is believed that the main preservation effects of rhEPO are the elimination of cytopathy/cell death, as derived from the resulting ischemic condition that extends to the target organ before ischemia occurs. In this examination, no direct effects of rhEPO administration on the emergence of active oxygen were observed. It is therefore suggested that there is a possibility of preserving the renal function in marginal donors with a longer agonal stage by effectively using rhEPO.
Moriyama
Manabu T
MT
Department of Urogenital Surgery, Knazawa Medical University, Ishikawa, Japan. moriyama@kanazawa-med.ac.jp
Tanaka
Tatsuro
T
Morita
Nobuyo
N
Ishii
Takeo
T
Chikazawa
Ippei
I
Suga
Kodai
K
Miyazawa
Katsuhito
K
Suzuki
Koji
K
D000209:Acute-Phase Proteins / Q000652:urine; D000818:Animals; D001806:Blood Urea Nitrogen; D002452:Cell Count; D003404:Creatinine / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D004921:Erythropoietin / Q000494:pharmacology*; D006801:Humans; D020287:In Situ Nick-End Labeling; D007668:Kidney / Q000187:drug effects* / Q000473:pathology*; D000071068:Lipocalin-2; D054834:Lipocalins / Q000652:urine; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D020011:Protective Agents / Q000494:pharmacology*; D011518:Proto-Oncogene Proteins / Q000652:urine; D051381:Rats; D017382:Reactive Oxygen Species / Q000378:metabolism; D011994:Recombinant Proteins; D015427:Reperfusion Injury / Q000097:blood / Q000517:prevention & control* / Q000652:urine
D000209:Acute-Phase Proteins; C097278:Lcn2 protein, rat; D000071068:Lipocalin-2; D054834:Lipocalins; D020011:Protective Agents; D011518:Proto-Oncogene Proteins; D017382:Reactive Oxygen Species; D011994:Recombinant Proteins; D004921:Erythropoietin; D003404:Creatinine